Please print and bring the requisition to your healthcare provider for signature. Unsigned requisitions will NOT be accepted at any LifeLabs® location.
If your healthcare provider has already given you a signed paper requisition, please bring it directly to a LifeLabs® location to pay and complete your testing.
Liver Fibrosis Test - Enhanced Liver Fibrosis (ELF) ScoreEnhanced Liver Fibrosis (ELF) Score is a simple, accurate, non-invasive blood test that measures the levels of three markers to estimate the rate of liver extracellular matrix metabolism which reflects the severity of liver fibrosis. ELF Score is recommended by the American Association of Clinical Endocrinology (AACE) as a second level test for the screening for liver fibrosis in patients with equivocal FIB-4 score.
About Liver Fibrosis Test - Enhanced Liver Fibrosis (ELF™) Score
Who is this test for?
In 2022, LifeLabs® introduced the Fibrosis-4 index (FIB-4) in Ontario, which is the first preferred test by the recent American Association of Clinical Endocrinology (AACE) guidelines. In our efforts to cover recommended tests for Non-Alcoholic Fatty Liver Disease (NAFLD) patients, we are pleased to share that we have also introduced the Enhanced Liver Fibrosis Score (ELF™) in Ontario. ELF™ is useful in assessing the severity of liver fibrosis and the level of risk for NAFLD patients to determine if a referral to a specialist is needed. By using the FIB-4 and ELF™ score the need for unnecessary biopsies can potentially be reduced.
Patients with the following conditions should be screened for NAFLD and advanced fibrosis:
- Obesity and/or features of metabolic syndrome
- Prediabetes or Type 2 diabetes with cardiometabolic risk factors
- Hepatic steatosis on any imaging study and/or
- Persistently elevated plasma aminotransferase levels (over 6 months)
- Persons belonging to the “high-risk” groups who have an indeterminate or high FIB-4 score for further workup with an ELF™ test or a transient elastography (LSM), as available.
What is this test used for?
Among the current and growing number of NAFLD patients, there is an urgent need for the early and accurate identification of patients at risk of progressing to cirrhosis and liver-related events (LRE). Enhanced Liver Fibrosis Score (ELF™) offers promising clinical utility in defining the progression of Non-alcoholic fatty liver disease (NAFLD) to cirrhosis and LREs in patients with an increased risk of advanced fibrosis. The ELF™ Score is designed to be an intermediate screening step between a simple test like Fibrosis-4 (FIB-4) and a more advanced test like fibro scan, or an invasive test like liver biopsy. Leveraging this screening tool can help reduce unnecessary referrals to other specialists and/or invasive and costly procedures, thus relieving wait times on diagnoses and treatments for patients and healthcare providers.
Test Turnaround Time
Results available within 6-10 business days
LifeLabs® Patient Service Centre (ON)